

DIAGNOSIS-BASED TREATMENT GUIDELINE ADHERENCE INDICATORS

Diagnosis	Indicator	Claims Measure	Treatment Record Measure
Major Depression	Psychiatric evaluation or treatment within 30 and 90 days of a new episode of care		X
	Mood symptoms and suicidality are assessed at every visit		X
	Comorbid problems are assessed upon initial evaluation and at least annually		X
	When medication is prescribed, there is evidence of consistency among the signs and symptoms, diagnosis, and medication prescribed		X
Schizophrenia	Psychiatric evaluation of treatment within 14 and 90 days of a new episode of care		X
	Evidence of assessment of positive signs of psychosis, (e.g., delusions +/-or hallucinations)		X
	Comorbid problems are assessed upon initial evaluation and at least annually		X
	When medication is prescribed, there is evidence of consistency among the signs and symptoms, diagnosis, and medication prescribed.		X

Diagnosis	Indicator	Claims Measure	Treatment Record Measure
	When antipsychotic medications are prescribed, there is evidence of observation for side effects, including EPS such as dystonic reactions, akathisia (“can’t sit still”), or akinesia		X
ADHD	Psychiatric evaluation or treatment within 60 days of new episode of care		X
	Active involvement of the family/primary caretakers in the assessment and treatment of the patient, unless contraindicated. (Child/Adolescent cases only)		X
	Education about ADHD and parent training in behavioral management provided (Child/Adolescent cases only)		X
	Comorbid problems are assessed upon initial evaluation and at least semi-annually		X
	When medication is prescribed, there is evidence of consistency among the signs and symptoms, diagnosis, and medication prescribed		X
	When medication is prescribed, there is evidence of an evaluation of the patient’s response to medication and adjustments as needed		X
Bipolar Disorder	If not initially seen by a psychiatrist, the patient should receive a psychiatric evaluation within 14 days of initial diagnosis		X

Diagnosis	Indicator	Claims Measure	Treatment Record Measure
	Mood symptoms and suicidality are assessed at every visit		X
	Comorbid problems are assessed upon initial evaluation and at least annually		X
	When medication is prescribed, there is evidence of consistency among the signs and symptoms, diagnosis, and medication prescribed		X
	When lithium is prescribed, there is a lithium level measurement and evidence of thyroid test measures		X
	If Depakote is prescribed, there is evidence of a valproic acid blood level and liver function tests		X
Co-Occurring Disorders	Treatment plan includes identification of barriers to adherence and interventions that address these barriers		X
	Treatment plan includes relapse plan, including identification of relapse triggers, skills needed to deal with triggers, and contingency plan for difficult instances		X
	Treatment plan includes both SA and psychiatric issues and interventions		X

Diagnosis	Indicator	Claims Measure	Treatment Record Measure
Opioid-Related Disorders	Withdrawal evaluation completed within 24 hours to determine the level of detoxification services needed (level I D through level IV D, refer to ASAM PPC-2)		X
	The evaluation includes the documentation of consideration of appropriate pharmacotherapy for substance abuse disorder. Rationale is provided for each component of the treatment plan including additional medications		X
	Co-occurring disorders should be assessed to identify both medical and psychiatric symptoms, which may be masked by substance abuse. If a co-occurring disorder is present, there must be evidence of coordination of care with the medical provider		X
	Evaluation of behaviors correlated with continuing use and abuse of illicit drugs		X
	Family/support system involvement in treatment, when appropriate		X